Quick Answer
INTEGRATED BIOPHARMA INC reported Operating Income Loss of $2.02 million for the year ending 2025.
- INTEGRATED BIOPHARMA INC showed an increase of +704.8% in Operating Income Loss from 2024 to 2025.
- This data is from INTEGRATED BIOPHARMA INC's annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), INTEGRATED BIOPHARMA INC's Operating Income Loss has grown by 658.0%.
- Historical annual values: Fiscal year 2025: $2.02 million | Fiscal year 2024: $251.0 thousand | Fiscal year 2023: $120.0 thousand | Fiscal year 2022: $2.75 million | Fiscal year 2021: $5.78 million | Fiscal year 2020: $3.26 million | Fiscal year 2019: $2.70 million | Fiscal year 2018: $1.69 million | Fiscal year 2017: $3.19 million | Fiscal year 2016: $2.11 million | Fiscal year 2015: $933.0 thousand | Fiscal year 2014: $1.35 million | Fiscal year 2013: $1.12 million | Fiscal year 2012: -$506.0 thousand | Fiscal year 2011: -$362.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: